She added that physicians chose IBTROZI for more than half of newly treated first-line patients during that period. Nuvation said adverse-event-driven discontinuations have remained low, with discontinuations concentrated among later-line patients with more extensive disease and prior treatment exposure. For the first six months of 2026, Nuvation reported total revenue of $114.9 million, including $41.7 million of IBTROZI net U.S. product revenue. About Nuvation Bio (NYSE:NUVB)Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.